Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells
Conclusions: Our study showed that HDACi enhanced recognition of glioma cell by immune cells and sensitivity of tumor immunotherapy, and improved the anti-tumor effect of tumor lysate vaccine through activating CTL immune response. These pharmacological molecular mechanisms of increasing immune recognition suggest that epigenetic modulation is a promising strategy for sensitizing immunotherapy for glioma treatment.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Ting Sun, Yanyan Li, Wei Yang, Haibin Wu, Xuetao Li, Yulun Huang, Youxin Zhou, Ziwei Du Tags: Research Paper Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Cancer Vaccines | Glioma | Immunotherapy | Study | Vaccines